全文获取类型
收费全文 | 1681篇 |
免费 | 119篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 66篇 |
妇产科学 | 14篇 |
基础医学 | 165篇 |
口腔科学 | 32篇 |
临床医学 | 226篇 |
内科学 | 556篇 |
皮肤病学 | 13篇 |
神经病学 | 104篇 |
特种医学 | 271篇 |
外科学 | 131篇 |
综合类 | 35篇 |
预防医学 | 60篇 |
眼科学 | 32篇 |
药学 | 47篇 |
中国医学 | 5篇 |
肿瘤学 | 46篇 |
出版年
2023年 | 15篇 |
2022年 | 9篇 |
2021年 | 26篇 |
2020年 | 16篇 |
2019年 | 31篇 |
2018年 | 47篇 |
2017年 | 21篇 |
2016年 | 27篇 |
2015年 | 27篇 |
2014年 | 46篇 |
2013年 | 50篇 |
2012年 | 56篇 |
2011年 | 60篇 |
2010年 | 52篇 |
2009年 | 71篇 |
2008年 | 60篇 |
2007年 | 50篇 |
2006年 | 63篇 |
2005年 | 44篇 |
2004年 | 39篇 |
2003年 | 41篇 |
2002年 | 38篇 |
2001年 | 38篇 |
2000年 | 28篇 |
1999年 | 24篇 |
1998年 | 52篇 |
1997年 | 55篇 |
1996年 | 66篇 |
1995年 | 52篇 |
1994年 | 47篇 |
1993年 | 52篇 |
1992年 | 35篇 |
1991年 | 38篇 |
1990年 | 31篇 |
1989年 | 45篇 |
1988年 | 41篇 |
1987年 | 44篇 |
1986年 | 49篇 |
1985年 | 33篇 |
1984年 | 20篇 |
1983年 | 19篇 |
1982年 | 29篇 |
1981年 | 18篇 |
1980年 | 14篇 |
1979年 | 6篇 |
1978年 | 7篇 |
1977年 | 12篇 |
1976年 | 14篇 |
1975年 | 14篇 |
1967年 | 4篇 |
排序方式: 共有1807条查询结果,搜索用时 31 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
Alfred E Buxton Hugh Calkins David J Callans John P DiMarco John D Fisher H Leon Greene David E Haines David L Hayes Paul A Heidenreich John M Miller Athena Poppas Eric N Prystowsky Mark H Schoenfeld Peter J Zimetbaum Paul A Heidenreich David C Goff Frederick L Grover David J Malenka Eric D Peterson Martha J Radford Rita F Redberg 《Journal of the American College of Cardiology》2006,48(11):2360-2396
3.
4.
5.
6.
7.
8.
9.
10.
Dr Gerald A. Maccioli MD Daniel R. Kuni MS George Silvay MD PhD John M. Evans MB Jerry M. Calkins MD PhD Joel A. Kaplan MD 《Journal of clinical monitoring and computing》1988,4(4):247-255
A multiple-center study was performed to determine the relationship between lower esophageal contractility, clinical signs, and anesthetic concentration as expressed by minimum alveolar concentration (MAC). One hundred four American Society of Anesthesiologists Class I through III patients were exposed to isoflurane (with and without nitrous oxide) or halothane in concentrations of 0.5, 1.0, and 1.5 MAC. Heart rate and systolic blood pressure were continuously monitored. Both the amplitude and frequency of spontaneous and provoked lower esophageal contractions were measured in situ by using a 24-F probe equipped with provoking and measuring balloons. Combined results demonstrated statistically significant correlations (P<0.001) between lower esophageal contractility and MAC. Spontaneous lower esophageal contractions decreased from 1.10±0.12 (SEM) contractions per minute (0.5 MAC) to 0.42±0.05 (1 MAC) to 0.18±0.05 (1.5 MAC). Provoked lower esophageal contractility values decreased from 45±4 mm Hg (0.5 MAC) to 29±3 (1 MAC) to 19±2 (1.5 MAC). Heart rate changes did not correlate with MAC, and systolic blood pressure correlated in only one of three centers. Intracenter and intercenter analyses failed to demonstrate a significant relationship between lower esophageal contractility and heart rate or systolic blood pressure. No intracenter differences in either amplitude or frequency of lower esophageal contractions were observed, despite differences in volatile agents, induction techniques and agents, patient populations, and duration of anesthesia. Our studies indicate that lower esophageal contractility may be an indicator of anesthetic depth as reflected by MAC, but further studies are needed to quantify the effects of surgical stimulus, intravenous anesthetics, vasodilators, anticholinergics, calcium channel blockers, beta-adrenergic agonists, and the presence of a nasogastric tube. 相似文献